



## **Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference**

August 30, 2022

ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDY) ("Bluejay", "the Company"), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that Neil Dey, Chief Executive Officer, and Kenneth Fisher, Chief Financial Officer, will present at the H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference taking place on September 12-14, 2022, at the Lotte Palace Hotel in New York City.

### **H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference**

Date: Tuesday, September 13, 2022  
Time: 10:30 AM ET

The Bluejay management team will also participate in one-on-one meetings during the event. Investors interested in meeting with Bluejay at the conference should contact their H.C. Wainwright representative.

#### ***About Bluejay Diagnostics:***

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis triage, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions. More information is available at [www.bluejaydx.com](http://www.bluejaydx.com).

#### **Investor Contact:**

Alexandra Schuman  
LifeSci Advisors  
[alex@lifesciadvisors.com](mailto:alex@lifesciadvisors.com)  
t: 646-876-3647